[go: up one dir, main page]

Cassidy, 1993 - Google Patents

Studies on 5-Aminosalicylic Acid and Its Use in the Treatment of Acute Pancreatitis

Cassidy, 1993

Document ID
620816509978913800
Author
Cassidy O
Publication year
Publication venue
PQDT-Global

External Links

Snippet

Increasing evidence incriminates oxidative stress as both the initiator of acinar cell injury and the amplifier/perpetuator towards multiorgan failure in experimental acute pancreatitis. The latter phase seems to involve damage via hypochlorous acid (HOCl) which is released …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients

Similar Documents

Publication Publication Date Title
Batinic-Haberle et al. SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways
Zingarelli et al. Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase
Lebrecht et al. Role of mtDNA lesions in anthracycline cardiotoxicity
Marques-Aleixo et al. Physical exercise mitigates doxorubicin-induced brain cortex and cerebellum mitochondrial alterations and cellular quality control signaling
Tahan et al. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats
Zou et al. Pioglitazone protects against renal ischemia-reperfusion injury by enhancing antioxidant capacity
Singh et al. Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI‐0052 (marizomib) in a human plasmacytoma xenograft murine model
ES2451715T3 (en) Use of cilastatin to reduce the nephrotoxicity of different compounds
Nourani et al. Cellular and molecular mechanisms of acute exposure to sulfur mustard: a systematic review
Merenda et al. Clinical treatments for mitochondrial dysfunctions after brain injury
Nabekura et al. Delay of cataract development in hereditary cataract UPL rats by disulfiram and aminoguanidine
Ding et al. Recent insights about autophagy in pancreatitis
Rambach et al. Secretion of a fungal protease represents a complement evasion mechanism in cerebral aspergillosis
Han et al. Hydroxycitric acid tripotassium inhibits calcium oxalate crystal formation in the Drosophila melanogaster model of hyperoxaluria
Choi et al. Co-administration of everolimus and N-acetylcysteine attenuates hepatic stellate cell activation and hepatic fibrosis
Fu et al. Dual therapy with phospholipase and metalloproteinase inhibitors from Sinonatrix annularis alleviated acute kidney and liver injury caused by multiple snake venoms
CA2830962A1 (en) Otamixaban formulations with improved stability
Rasoulian et al. Effects of pretreatment with single-dose or intermittent oxygen on Cisplatin-induced nephrotoxicity in rats
Vasina et al. Non-peptidyl low molecular weight radical scavenger IAC attenuates DSS-induced colitis in rats
Fawzy et al. Mito-TEMPO improved L-Arginine-induced acute pancreatitis in rats via TLR-4/NF-кB/NLRP3 inflammasome downregulation and antioxidant properties
Cassidy Studies on 5-Aminosalicylic Acid and Its Use in the Treatment of Acute Pancreatitis
Henke Superoxide dismutase mimics as future therapeutics
Alam et al. Alloxan induced diabetes in rabbits
US7351722B2 (en) Use of Mangafodipir for treating oxidative stress effects
Oak et al. The effects of glutathione glycosidein acetaminophen-induced liver cell necrosis